Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2025-04-08 Director's Dealing
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
114年03月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by company insiders, including directors, supervisors, and senior management, showing their current holdings, pledged shares, and related information. It is focused on insider shareholdings and does not contain financial statements, earnings data, or management discussion. The document is not a report or announcement of financial results, nor is it a regulatory filing about changes in board or management. It specifically reports insider shareholdings, which corresponds to the category 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives. Although the document does not explicitly mention transactions, it is a disclosure of insider holdings, which fits best under DIRS rather than other categories. The document length is under 5,000 characters, but it contains detailed insider shareholding data, not just an announcement or certification, so it is not RPA or RNS. Therefore, the best classification is DIRS with high confidence.
2025-04-08 Chinese
113年度財務比率
Fund Information / Factsheet Classification · 95% confidence The document contains a financial data analysis for the company 美時 (Mei Shi) over three fiscal years (111年度, 112年度, 113年度). The data includes financial ratios such as debt to asset ratio, liquidity ratios, turnover ratios, profitability ratios, and cash flow ratios. The document is relatively short (1019 characters) and presents summarized financial metrics rather than detailed financial statements or narrative management discussion. There is no indication that this is a full annual or interim report, nor is it an announcement or certification. The content resembles a brief financial summary or factsheet presenting key financial data points for multiple years. Given the concise nature and focus on key financial facts, the document best fits the category of Fund Information / Factsheet (FS).
2025-03-31 Chinese
113年第4季海外子公司投資
Regulatory Filings Classification · 90% confidence The document is a detailed tabular disclosure of investment holdings and investment income/losses related to overseas subsidiaries for a specific quarter (113th year, 4th quarter). It includes financial figures such as original investment amounts, investment balances, and recognized investment gains or losses. The document is relatively short (2741 characters) and does not contain a full financial report or comprehensive financial statements. It appears to be a regulatory disclosure related to investment holdings rather than a full annual or interim report. There is no indication that this is an announcement of a report publication or a certification. Given the nature of the content and the lack of a full report, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2025-03-31 Chinese
代重要子公司Alvogen Korea Holdings Ltd.公告2025年股東 常會重要決議事項
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement from a company (Alvogen Korea Holdings Ltd.) regarding the resolutions passed at its 2025 Annual General Meeting (股東常會). It lists key decisions such as approval of the 2024 financial statements, approval of directors' and supervisors' remuneration, and other meeting outcomes. The content is focused on the results of shareholder voting at the AGM rather than the full report or detailed financial statements themselves. The document length is short (654 characters), consistent with a voting results announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-27 Chinese
代重要子公司Alvogen Korea Co., Ltd.公告2025年股東常會 重要決議事項
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement from a company regarding the resolutions passed at the 2025 Annual General Meeting (AGM) of its important subsidiary, Alvogen Korea Co., Ltd. It lists key decisions such as approval of the 2024 financial statements, approval of directors' and supervisors' remuneration, and other AGM-related matters. The document is short (650 characters) and primarily reports the results of the shareholder meeting rather than providing detailed financial statements or full reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-27 Chinese
113年第4季大陸投資
Regulatory Filings Classification · 90% confidence The document is a detailed tabular disclosure of investment amounts and related financial data concerning investments in mainland China by a Taiwanese listed company. It includes specific financial figures, investment methods, and regulatory limits. The content is focused on investment details rather than a full financial report or announcement. The document length is short (1442 characters), but it contains substantive financial data related to investments. This type of disclosure aligns with regulatory filings related to investment information rather than a full annual or interim report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory disclosure about investment activities, which fits best under Regulatory Filings (RNS).
2025-03-19 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.